Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. Financials
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Real-time Estimate Cboe BZX  -  02:45 2022-10-05 pm EDT
3.130 USD   +9.44%
09/07CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
AQ
08/12Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT
08/11Transcript : CorMedix Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 187239173118--
Enterprise Value (EV)1 18719710867,559,8118
P/E ratio -4,04x-9,65x-6,07x-3,35x-3,35x-4,93x
Yield ------
Capitalization / Revenue 659x997x907x12 181x115x7,60x
EV / Revenue 659x822x564x6 983x58,2x7,60x
EV / EBITDA -8 913 104x-7 259 375x----
Price to Book -4,80x2,76x2,34x2,92x-
Nbr of stocks (in thousands) 25 63132 11138 06541 186--
Reference price (USD) 7,287,434,552,862,862,86
Announcement Date 03/16/202003/30/202103/29/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 0,280,240,190,011,0315,5
EBITDA -20,9-27,1----
Operating profit (EBIT)1 -21,0-27,2-29,4-33,2-42,5-30,0
Operating Margin -7 416%-11 378%-15 417%-343 190%-4 133%-194%
Pre-Tax Profit (EBT)1 --27,2-29,5-33,1-42,5-30,0
Net income1 -43,5-22,0-28,2-33,9-45,8-30,0
Net margin -15 369%-9 208%-14 774%-350 359%-4 451%-194%
EPS2 -1,80-0,77-0,75-0,85-0,85-0,58
Dividend per Share ------
Announcement Date 03/16/202003/30/202103/29/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 0,060,010,02---
EBITDA ------
Operating profit (EBIT)1 -7,78-7,03-8,24-8,85-9,05-11,0
Operating Margin -13 794%-92 047%-38 779%---
Pre-Tax Profit (EBT)1 -7,79-7,03-8,19-8,85-9,05-11,0
Net income1 -7,79-7,03-7,60-8,85-9,05-11,0
Net margin -13 814%-92 071%-35 787%---
EPS2 -0,20-0,18-0,19-0,23-0,24-0,25
Dividend per Share ------
Announcement Date 03/29/202205/12/202208/11/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 -41,965,550,358,0-
Leverage (Debt / EBITDA) -1,55x----
Free Cash Flow1 -15,1-22,1-22,6-29,2-44,9-
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 -1,551,651,220,98-
Cash Flow per Share ------
Capex1 -0,111,430,020,02-
Capex / Sales -47,1%746%248%1,95%-
Announcement Date 03/16/202003/30/202103/29/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 117 793 041
Net sales (USD) 190 940
Number of employees 30
Sales / Employee (USD) 6 365
Free-Float 98,8%
Free-Float capitalization (USD) 116 334 528
Avg. Exchange 20 sessions (USD) 495 985
Average Daily Capital Traded 0,42%
EPS & Dividend